Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib

Few trial-based assessments of ruxolitinib in patients with lower-risk myelofibrosis (MF) have been conducted, and no studies have made such assessments in a real-world population. We assessed changes in spleen size and constitutional symptoms during ruxolitinib treatment using a retrospective, obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Keith L., Côté, Isabelle, Kaye, James A., Mendelson, Estella, Gao, Haitao, Perez Ronco, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655278/
https://www.ncbi.nlm.nih.gov/pubmed/26635878
http://dx.doi.org/10.1155/2015/848473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655278/
https://www.ncbi.nlm.nih.gov/pubmed/26635878
http://dx.doi.org/10.1155/2015/848473

Ejemplares similares